Neogen (NEOG) Resumen de Acciones
Neogen Corporation desarrolla, fabrica y comercializa diversos productos y servicios para la seguridad alimentaria y animal en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
NEOG Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Neogen Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$11.92 |
| Máximo en las últimas 52 semanas | US$12.85 |
| Mínimo de 52 semanas | US$4.90 |
| Beta | 1.76 |
| Cambio en 1 mes | 4.56% |
| Variación en 3 meses | 28.93% |
| Cambio de 1 año | 113.24% |
| Variación en 3 años | -44.36% |
| Variación en 5 años | -71.58% |
| Variación desde la OPV | 4,564.27% |
Noticias y actualizaciones recientes
Actualización de narrativa • Sep 03
NEOG: 2027 Revenue Outlook And Screwworm Response Will Drive Bullish Case
Analysts have raised their price target on Neogen from $13 to $14, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and a revised future P/E expectation. What’s in the News for Neogen Neogen issued earnings guidance for the first quarter of fiscal 2027, with expected revenue in a range of $207 million to $209 million.
Actualización de narrativa • Aug 15
NEOG: Transformation Plan And Higher R&D Spending Will Shape Balanced Outlook
Analysts have raised their price target for Neogen to $12.00 from $11, citing modest adjustments to fair value estimates, a slightly lower discount rate, a smaller expected revenue decline, a stable profit margin outlook, and a marginally higher assumed future P/E multiple. What’s in the News for Neogen Neogen reported fiscal Q4 2026 revenue of US$225.3 million and a net loss of US$11.3 million, with core revenue growth of 4.3%, mainly from the Food Safety segment.Recent updates
Actualización de narrativa • Sep 03
NEOG: 2027 Revenue Outlook And Screwworm Response Will Drive Bullish Case
Analysts have raised their price target on Neogen from $13 to $14, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and a revised future P/E expectation. What’s in the News for Neogen Neogen issued earnings guidance for the first quarter of fiscal 2027, with expected revenue in a range of $207 million to $209 million.Actualización de narrativa • Aug 15
NEOG: Transformation Plan And Higher R&D Spending Will Shape Balanced Outlook
Analysts have raised their price target for Neogen to $12.00 from $11, citing modest adjustments to fair value estimates, a slightly lower discount rate, a smaller expected revenue decline, a stable profit margin outlook, and a marginally higher assumed future P/E multiple. What’s in the News for Neogen Neogen reported fiscal Q4 2026 revenue of US$225.3 million and a net loss of US$11.3 million, with core revenue growth of 4.3%, mainly from the Food Safety segment.
Actualización de narrativa • Aug 01
NEOG: 2027 Guidance And Margin Outlook Will Frame Balanced Return Potential
Analysts have raised their fair value estimate for Neogen from $12 to $13, citing updated assumptions around a lower discount rate, a projected shift to positive revenue growth, a slightly lower profit margin, and a higher future P/E multiple. What's in the News for Neogen Neogen issued earnings guidance for the first quarter of fiscal 2027, with expected revenue in a range of $207 million to $209 million.Seeking Alpha • Jun 27
Neogen: Still A Difficult Story
Summary Neogen has addressed urgent deleveraging needs through divestments and cost-cutting, but earnings power remains modest, and recent divestments were at low sales multiples. Q3 results were mixed: core food safety sales grew 4%, the animal segment fell 8% due to a supplier issue, and adjusted EBITDA margin rose to 22.8%. The $160M genomics business sale to Zoetis reduces net debt below $500M but was completed at only 1.5x sales, reflecting lagging margins and limited immediate value creation. Pro forma sales are now ~$800M, with realistic earnings estimates of $0.30-$0.45/share; organic growth and margin improvement remain critical for re-rating. Read the full article on Seeking AlphaActualización de narrativa • Jun 23
NEOG: Screwworm Response And Buybacks Will Support Bullish 2026 Outlook
Analysts have modestly revised their Neogen price target to $13.00, reflecting updated assumptions around a slightly lower discount rate, softer revenue growth expectations, reduced profit margins, and a higher future P/E multiple in their valuation models. What's in the News for Neogen Neogen expanded FIFRA Section 2(ee) recommendations for its Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol products to support New World Screwworm response efforts in livestock, with approvals in Texas and availability in Florida.Actualización de narrativa • Jun 08
NEOG: Food Safety Execution And Manufacturing Shift Will Support Future Upside
Analysts have raised their price target on Neogen to $11.00. This reflects updated assumptions that include a slightly lower discount rate, a smaller expected decline in revenue growth, a marginally higher profit margin, and a modestly reduced future P/E multiple.Actualización de narrativa • May 25
NEOG: Raised 2026 Revenue Guidance And Higher P/E Expectation Will Support Upside
Analysts have raised their price target for Neogen to $11.00 from $10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher expected future P/E multiple. What's in the News Neogen issued updated guidance for fiscal 2026, focusing on its outlook for full year revenue (Key Developments).Actualización de narrativa • Apr 30
NEOG: Updated 2026 Revenue Outlook Will Support Future Upside Potential
Analysts have nudged their price target on Neogen slightly higher to $12, reflecting updated assumptions around discount rate, profit margin and future P/E that keep fair value broadly in line with prior estimates. What's in the News Neogen updated full fiscal year 2026 guidance, with projected revenue now in a range of $857 million to $860 million.Actualización de narrativa • Apr 15
NEOG: Recall Response And Updated 2026 Guidance Will Support Future Upside
Analysts have raised their price target on Neogen from $11.67 to $12.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher future P/E of 32.21 compared with 28.61 previously. What's in the News Neogen updated full fiscal year 2026 guidance, indicating expected revenue in a range of $857 million to $860 million, compared with prior guidance of $845 million to $855 million (corporate guidance).Actualización de narrativa • Apr 01
NEOG: Earnings Outlook Will Benefit From Recall Actions And New Guidance
Analysts have raised their price target on Neogen from $8.17 to $11.67 per share, citing updated assumptions related to the discount rate, revenue growth, profit margins, and a higher future P/E multiple. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials.Actualización de narrativa • Mar 18
NEOG: Recall Resolution Will Shape Bullish View On 2026 Revenue Outlook
Analysts have kept Neogen's price target steady at $13.00, indicating only minor adjustments in assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials, and is extending the recall to 2 mL / 20 mg vials while its investigation continues (Key Developments).Actualización de narrativa • Mar 04
NEOG: 2026 Outlook Will Rely On Recall Resolution For Upside
Analysts are holding Neogen's fair value estimate at $13.00 while modestly adjusting their assumptions around the discount rate, long term revenue trends, profit margins, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the overall price target level.Actualización de narrativa • Feb 18
NEOG: 2026 Revenue Outlook Will Support Continued Bullish Thesis
Analysts have maintained Neogen's price target at $13.00, noting that only minor adjustments to assumptions around discount rate, revenue growth, profit margins, and future P/E were made, which do not materially change their valuation view. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level, after microbial contamination was identified in certain 10 mL/50 mg vials used via intraarticular injection, which is inconsistent with the product's labeled use (Key Developments).Actualización de narrativa • Feb 03
NEOG: Higher Forward P/E And 2026 Outlook Will Support Bullish Thesis
Analysts have raised their price target on Neogen by an implied $3 per share, pointing to adjustments in fair value, discount rate, revenue growth expectations, profit margin assumptions, and a higher forward P/E multiple as the key drivers behind the change. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL/50 mg vials, with an expanded recall to 2 mL/20 mg vials while the investigation continues (Key Developments).Artículo de análisis • Feb 02
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 46% Jump Looks Justified
Despite an already strong run, Neogen Corporation ( NASDAQ:NEOG ) shares have been powering on, with a gain of 46% in...Actualización de narrativa • Jan 20
NEOG: Future CFO Transition And 2026 Guidance Will Support Measured Outlook
Analysts have raised their fair value estimate for Neogen from US$6.50 to US$10.00, reflecting updated assumptions regarding discount rates, revenue trends, profit margins and a higher future P/E multiple. What's in the News Neogen issued earnings guidance for fiscal 2026, with revenue anticipated in the range of US$845 million to US$855 million, giving investors a sense of management’s current expectations for the business (Key Developments).Actualización de narrativa • Jan 05
NEOG: New CFO Appointment Will Support Confidence In Earnings Outlook
Analysts now place a higher implied value on Neogen, lifting their fair value estimate from US$8.00 to US$10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a richer future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer, effective November 3, 2025.Artículo de análisis • Dec 19
Neogen Corporation (NASDAQ:NEOG) Shares Fly 34% But Investors Aren't Buying For Growth
The Neogen Corporation ( NASDAQ:NEOG ) share price has done very well over the last month, posting an excellent gain of...Actualización de narrativa • Dec 17
NEOG: Future CFO Transition And Guidance Stability Will Support Measured Outlook
Analysts have raised their price target on Neogen from approximately $5.00 to $6.50 per share, citing a slightly lower discount rate, modestly improved revenue trajectory, better profit margin expectations, and a willingness to assign a higher future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025, with outgoing CFO David Naemura supporting the transition through year end.Actualización de narrativa • Dec 03
NEOG: CFO Transition And Alliance Renewal Will Support Future Earnings
Analysts have modestly raised their price target on Neogen by about $0.20 per share, citing a slightly higher assumed discount rate and marginally richer future valuation multiples that together offset minor tweaks to long term growth and margin expectations. What's in the News Reaffirmed fiscal 2026 earnings guidance, maintaining full-year revenue expectations of $820 million to $840 million (company guidance).Actualización de narrativa • Nov 19
NEOG: Profit Margin Expansion And CFO Transition Will Drive Earnings Potential
Analysts have raised their price target for Neogen modestly, citing improved profit margin projections and a slightly lower expected future price-to-earnings ratio as key factors behind the adjustment. What's in the News Neogen appointed Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025.Actualización de narrativa • Oct 31
NEOG: Rising Profit Margins And New Partnerships Will Drive Future Expansion
Narrative Update: Neogen Analyst Price Target Revised Analysts have slightly raised their price target for Neogen, citing improvements in expected profit margins and a modest decline in projected future valuation multiples. This has resulted in a new estimated fair value of $8.17 per share.Actualización de narrativa • Oct 17
Food Safety Testing Advances Will Expand Global Opportunities
Neogen's analyst target price has risen from $7.67 to $8.17, as analysts point to improved revenue growth projections alongside a reduced discount rate, both supporting a higher valuation. What's in the News Neogen introduced Molecular Detection Assay: Listeria Right Now, a rapid, enrichment-free tool for detecting Listeria species with results in about two hours and streamlined workflow benefits (Product-Related Announcements).Actualización de narrativa • Oct 03
Food Safety Testing Advances Will Expand Global Opportunities
Analysts have raised their price target for Neogen from $6.50 to $7.67, citing a slightly lower discount rate and forward profit expectations. Revenue growth projections remain stable.Artículo de análisis • Jul 10
Is Neogen (NASDAQ:NEOG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Nueva narrativa • May 27
Food Safety And Genomics Will Expand Global Markets
Resilient core businesses, strategic divestitures, and efficiency initiatives are expected to stabilize revenue and expand margins as macro and operational conditions improve.Artículo de análisis • May 16
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 33% Jump Looks Justified
Those holding Neogen Corporation ( NASDAQ:NEOG ) shares would be relieved that the share price has rebounded 33% in the...Seeking Alpha • Apr 23
Neogen: A Fair Divestment (Rating Upgrade)
Summary Neogen's merger with 3M Food Safety led to significant debt and operational struggles, causing shares to plummet and the CEO to be ousted. Following disappointing sales and earnings, the company is exploring asset sales and restructuring, offering potential upside if stabilization occurs. Neogen's current valuation appears modest relative to sales, presenting a speculative opportunity for investors willing to take on risk. I am cautiously optimistic about Neogen's future, considering the potential for above-average returns if divestments are executed at reasonable valuations. Read the full article on Seeking AlphaArtículo de análisis • Apr 11
Here's Why Neogen (NASDAQ:NEOG) Is Weighed Down By Its Debt Load
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 14
Neogen: Food Safety Play Is Far From A Safe Pay
Summary Neogen Corporation's merger with 3M Food Safety in 2022 led to significant challenges, including valuation compression, debt increase, and underperformance, causing shares to plummet. Neogen's financial performance has been disappointing, with sales and EBITDA falling short of expectations and net debt increasing. The company's guidance for 2025 remains modest, and recent results have shown minimal revenue growth and high leverage ratios, frustrating investors. Trading at $12, NEOG's future hinges on management's ability to execute and deliver on promised EBITDA improvements to reduce leverage and boost earnings. Read the full article on Seeking AlphaArtículo de análisis • Dec 03
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
It's not a stretch to say that Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or "P/S") ratio of 3.3x right now...Artículo de análisis • Nov 07
Does Neogen (NASDAQ:NEOG) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rentabilidad de los accionistas
| NEOG | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 0.9% | -5.1% | -0.2% |
| 1Y | 113.2% | -17.5% | 14.8% |
Rentabilidad vs. Industria: NEOG superó a la industria US Medical Equipment, que obtuvo un rendimiento del -17.5% el año pasado.
Rentabilidad vs. Mercado: NEOG superó al mercado US, que obtuvo un rendimiento del 14.8% el año pasado.
Volatilidad de los precios
| NEOG volatility | |
|---|---|
| NEOG Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: NEOG no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de NEOG (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1981 | 2,636 | Mike Nassif | www.neogen.com |
Neogen Corporation desarrolla, fabrica y comercializa diversos productos y servicios relacionados con la seguridad alimentaria y la seguridad animal, tanto en Estados Unidos como a nivel internacional. Opera a través de los segmentos de Seguridad Alimentaria y Seguridad Animal. La empresa ofrece kits de pruebas de diagnóstico y productos complementarios para detectar sustancias peligrosas o no deseadas en los alimentos para consumo humano y en los piensos para animales, tales como patógenos transmitidos por los alimentos, organismos causantes de la descomposición, toxinas naturales, alérgenos alimentarios, subproductos de rumiantes, identificación de especies cárnicas, residuos de medicamentos, residuos de plaguicidas y problemas generales de higiene para los productores y procesadores de alimentos.
Resumen de fundamentos de Neogen Corporation
| Estadísticas fundamentales de NEOG | |
|---|---|
| Capitalización bursátil | US$2.59b |
| Beneficios(TTM) | -US$7.90m |
| Ingresos (TTM) | US$870.40m |
3.0x
Ratio precio-ventas (PS)-329.0x
Ratio precio-beneficio (PE)¿Está NEOG sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NEOG | |
|---|---|
| Ingresos | US$870.40m |
| Coste de los ingresos | US$461.90m |
| Beneficio bruto | US$408.50m |
| Otros gastos | US$416.40m |
| Beneficios | -US$7.90m |
Últimos beneficios comunicados
May 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.036 |
| Margen bruto | 46.93% |
| Margen de beneficio neto | -0.91% |
| Ratio deuda/patrimonio | 38.0% |
¿Cómo se ha desempeñado NEOG a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/09 22:16 |
| Precio de las acciones al final del día | 2026/09/09 00:00 |
| Beneficios | 2026/05/31 |
| Ingresos anuales | 2026/05/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Neogen Corporation está cubierta por 15 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Robert Labick | CJS Securities, Inc. |
| David Westenberg | CL King & Associates, Inc. |